Argos Therapeutics Receives 2014 Red Herring North America

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Argos Therapeutics Receives 2014 Red Herring North America Top 100 Award

DURHAM, N.C., Nov. 24, 2014 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq: ARGS ) ("Argos"), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on the Arcelis® technology platform, today announced the company has been honored with a 2014 Red Herring North America Top 100 award.

"We are delighted to be included on this list of North American companies developing truly revolutionary technologies founded on business models that have the potential to disrupt our respective markets," said Jeff Abbey, president and CEO of Argos. "It is an exciting time for Argos and the next few years will include important milestones as we continue to advance our patient-specific immunotherapies based on the Arcelis® technology platform through late stage clinical research."

Over the past two decades the Red Herring Top 100 awards have highlighted companies developing innovative technologies and business models. The Red Herring editorial team selects technology and life science companies based on criteria including level of specialty, social contribution, and revenues and growth rate.

"Aside from making potentially life-altering technology, Argos Therapeutics has also developed an efficient way to manufacture the treatments," noted the Red Herring editorial team.

The 2014 Top 100 winners in North America were announced at the Red Herring Global 2014 forum held in Los Angeles from November 18-20, 2014.

About the Arcelis® Technology Platform

Arcelis® is a fully personalized immunotherapy technology that captures mutated and variant antigens that are specific to each patient's disease. It is designed to overcome immunosuppression by producing a durable memory T-cell response without adjuvants that may be associated with toxicity. The technology is potentially applicable to a wide range of different cancers and infectious diseases and is designed to overcome many of the manufacturing and commercialization challenges that have impeded other personalized immunotherapies. The Arcelis® process uses only a small tumor or blood sample and the patient's own dendritic cells, which are collected and optimized following a single leukapheresis procedure. The proprietary process uses RNA isolated from the patient's disease sample to program dendritic cells to target disease antigens. The activated, antigen-loaded dendritic cells are then formulated into the patient's plasma and administered via intradermal injection.

About Argos Therapeutics

Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis® technology platform. Argos' most advanced product candidate, AGS-003, is being evaluated in the pivotal ADAPT phase 3 clinical trial for the treatment of metastatic renal cell carcinoma (mRCC). The Company is also developing a second Arcelis®-based product candidate, AGS-004, for the treatment of HIV, currently being evaluated in a phase 2 clinical trial in combination with a latency reversing drug for HIV eradication in adult patients. For more information about Argos Therapeutics, visit www.argostherapeutics.com .

Forward Looking Statements

Any statements in this press release about Argos' future expectations, plans and prospects, including statements about Argos and other statements containing the words "believes," "anticipates," "plans," "expects," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including whether Argos' cash resources will be sufficient to fund our continuing operations for the period anticipated; whether results obtained in clinical trials will be indicative of results obtained in future clinical trials; whether Argos' product candidates will advance through the clinical trial process on a timely basis and receive approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies; whether, if product candidates obtains approval, they will be successfully distributed and marketed; and other factors discussed in the "Risk Factors" section of Argos' Quarterly Report on Form 10-Q for the quarter ended June 30, 2014 which is on file with the SEC. In addition, the forward-looking statements included in this press release represent the Argos' views as of November 24, 2014. Argos anticipates that subsequent events and developments will cause Argos' views to change. However, while Argos may elect to update these forward-looking statements at some point in the future, Argos specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Argos' views as of any date subsequent to November 24, 2014.

Media contact: Adam Daley Berry & Company Public Relations 212-253-8881 Investor contact: Angeli Kolhatkar Burns McClellan 212-213-0006

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Early Dog Guarding Signs Matter Before a Sudden Growl

Updated Category News Views 104

A bowl, a chewed-up toy, or a patch of couch can turn tense in a heartbeat. That is why the useful part of Brian Manning's guidance is not some fantasy of making every dog endlessly tolerant; it is learning to notice discomfort while there is still room to back off safely. For anybody watching the pet-care and behavior-training field, this is the kind of plainspoken...

Continue Reading
Cold Stone’s Holiday Menu Is a Franchisee Traffic Test

Updated Category News Views 56

Peppermint, caramel, and red velvet arrive right when dessert budgets loosen up. Cold Stone Creamery has rolled out a holiday menu running through January 5, 2027, and this is the sort of modest, practical promotion that matters more to a franchise system than the glittery language around it. Nobody should confuse two seasonal ice cream flavors with a corporate...

Continue Reading
JLL’s Facility Management Push Gets a Useful Nod From Frost

Updated Category News Views 104

A Building Breaks Down Long Before the Earnings Call Notices Facility management is the sort of business that gets ignored until an airport system fails, a data-center cooling unit balks, or a workforce cannot use the building it was told to return to. That is why Frost & Sullivan’s 2026 recognition of JLL deserves more than the usual award-season shrug. It points to an...

Continue Reading
California's AI Oversight Roadmap Raises the Bar Early

Updated Category News Views 41

California has put a real set of teeth on the table, at least on paper. Governor Gavin Newsom's November 18 roadmap for implementing the state's new AI laws embraces an independent verification organization, or IVO, framework that Fathom has been pushing: outside evaluators, licensed by the state, examining whether frontier AI systems create catastrophic risks. For anyone...

Continue Reading
Albany Masonry Waterproofing Is a Quiet Value Play

Updated Category News Views 114

Winter works its mischief one soaked brick at a time. That is the unglamorous truth behind Sean Mulligan's discussion of masonry waterproofing for Albany-area homes. Brick and stone look tough enough to outlast the furniture, the siding, maybe the whole neighborhood. Yet they are porous materials, and in a region where rain, snowmelt, and sharp temperature swings keep...

Continue Reading
U.S. Patriot's Veteran Hiring Earns a Real National Nod

Updated Category News Views 58

A workforce award can be cheap wallpaper, but this one has some heft. U.S. Patriot, the veteran-founded and veteran-led military goods retailer owned by GALLS, landed on Military Times’ 2026 Best for Vets: Employers list, placing third in retail and first in Kentucky. The recognition covers 250 organizations, and this is U.S. Patriot’s fourth consecutive appearance....

Continue Reading
Rescue Dog Wines Puts Holiday Bottles to Work for Dogs

Updated Category News Views 66

A Bottle With a Job Beyond the Table Holiday wine promotions usually arrive wrapped in the same tired ribbon: buy more, save a little, pour it at a party, forget it by January. Rescue Dog Wines is taking a more grounded route. The family-owned Lodi-area winery says it gives 50% of profits to animal rescue organizations, and that commitment is not being dressed up as a...

Continue Reading
Hyster-Yale’s $135 Million Convert Carries Real Cost

Updated Category News Views 0

Forklift makers do not usually get to hide a 7.50% borrowing cost behind glossy financing jargon. Hyster-Yale has priced $135 million of convertible senior notes due in 2031, lifting the deal from the originally announced $125 million. There is also an option for initial purchasers to take another $20 million. For NYSE:HY shareholders, this is not a simple debt cleanup....

Continue Reading
Paladone Tests LEGO's Everyday Collectibles Pull Abroad

Updated Category News Views 139

A glowing minifigure lamp is not exactly a macroeconomic event, but licensed merchandise has a funny way of revealing where household spending still has a pulse. Paladone Products has put its first LEGO-branded collection into stores, a modest-looking launch with some real retail logic behind it. This is not a grand toy-box bet on one blockbuster item. It is a spread of...

Continue Reading
A €18 Million Mecca Chandelier Tests Austrian Craft

Updated Category News Views 229

Scale Is Easy to Boast About, Delivery Is Not A 34.1-metre chandelier hanging in Mecca is the sort of job that makes ordinary project talk sound downright silly. Lights of Vienna says it designed, built, tested, shipped and installed this monster for the Grand Mosque's Shamiya area, with a contract value of roughly €18 million. That is a serious piece of work for a...

Continue Reading

Top 5 Most Recently Viewed Articles

T-Mobile US to Showcase Innovations at Capital Markets Day

Updated Category News Views 104

T-Mobile US, Inc. Unveils Plans at Deutsche Telekom Capital Markets Day BELLEVUE, Wash. — T-Mobile US, Inc. (NASDAQ: TMUS) is gearing up to present at the highly anticipated Deutsche Telekom Capital Markets Day, a pivotal event that showcases the company's strategic vision and operational milestones. The presentation will feature insights from Mike Sievert, T-Mobile’s...

Continue Reading
Earnings Insights for Edwards Lifesciences: What to Expect

Updated Category News Views 84

Understanding Edwards Lifesciences's Expected Earnings Release Edwards Lifesciences (NYSE: EW) is gearing up to announce its quarterly earnings, creating a buzz among investors eager for insights on the company's performance. With analysts forecasting an earnings per share (EPS) of $0.65, stakeholders are looking forward to how these results may impact the stock price and...

Continue Reading
Understanding ezPaycheck: A Smart Solution for Restaurant Payroll

Updated Category News Views 139

Introducing ezPaycheck: Tailored Payroll Solution for Restaurants ezPaycheck is designed for restaurant owners who prioritize precision and efficiency in managing payroll. This cutting-edge software allows users to streamline their payroll processes, offering a risk-free trial for up to 30 days to evaluate compatibility with existing systems. Why Choose ezPaycheck for...

Continue Reading
Revolutionizing Pet Compliance with AI: PetScreening Unveils Tool

Updated Category News Views 638

PetScreening Introduces Innovative AI Compliance Tool The solution will help operators capture pet-related revenue that otherwise would have been lost. PetComply.ai Launch Today, PetScreening, a leader in pet policy compliance software, has launched PetComply.ai, an exclusive feature designed to assist property managers in identifying undisclosed pets by renters. This...

Continue Reading
STRATA Skin Sciences Announces Participation in Investor Conference

Updated Category News Views 99

STRATA Skin Sciences Joins the Benchmark Company Investor Conference STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a pioneering medical technology company focused on innovative solutions for dermatologic conditions, has announced participation in the upcoming Benchmark Company 13th Annual Discovery Investor Conference. This event will take place at the New York Athletic...

Continue Reading